Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer

• DOI: 10.3892/ol.2023.14002
• Publication Date: 2023-08-08T11:39:45Z
• Authors: Hiroyuki Iwasaki; Soji Toda; Akari Takahashi; Katsuhiko Masudo
• Keywords: Lenvatinib; Anaplastic thyroid cancer

Anaplastic thyroid cancer (ATC) is a very rare disease with poor prognosis and no established effective drug therapy. The present study aimed to report the outcomes of lenvatinib single-agent therapy as an initial treatment in ATC, investigate its safety efficacy. This retrospective cohort included 56 patients unresectable primary whom 36 were treated 12 weekly paclitaxel, 8 who refused any received palliative care. average survival group was 5.8 months, which significantly longer than 2.0 months paclitaxel (P=0.005). efficacy whose tumors unresectable, evaluated. response rate 33% median overall time 5.0 months. A review indicated that should be used under careful observation local findings. Two patients, showed reduction lenvatinib, underwent conversion surgery, prolonged terms avoiding events, such asphyxia, fistula hemorrhage due tumor growth; however, surgical margins positive, indicating complete remission impossible even if resection performed. Therefore, starting identifying therapeutic based on genomic analysis acceptable strategy for ATC while halting progression.